These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 19726453)

  • 1. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
    Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
    J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
    Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
    Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
    Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H; Saini S
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study.
    Kozloff MF; Berlin J; Flynn PJ; Kabbinavar F; Ashby M; Dong W; Sing AP; Grothey A
    Oncology; 2010; 78(5-6):329-39. PubMed ID: 20733336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
    Chen HX; Mooney M; Boron M; Vena D; Mosby K; Grochow L; Jaffe C; Rubinstein L; Zwiebel J; Kaplan RS
    J Clin Oncol; 2006 Jul; 24(21):3354-60. PubMed ID: 16849749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
    Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
    Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
    Wolff RA; Fuchs M; Di Bartolomeo M; Hossain AM; Stoffregen C; Nicol S; Heinemann V
    Cancer; 2012 Sep; 118(17):4132-8. PubMed ID: 22213153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
    J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
    Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
    Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
    Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
    Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
    Giantonio BJ
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of chemotherapy combined with bevacizumab for metastatic colorectal cancer].
    Momoi A; Motomura S; Hashimoto C; Takasaki H; Takemura S; Takagi S; Akaike M
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):79-83. PubMed ID: 21368462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
    Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.